Table 3 Correlation of RANBP10 expression with clinicopathological variables in CGGA datasets.
From: RANBP10 promotes glioblastoma progression by regulating the FBXW7/c-Myc pathway
Clinicopathological features | Cases | RANBP10 expression | F | P | ||
|---|---|---|---|---|---|---|
Low | High | |||||
Age | ≦42 | 167 | 88 | 79 | 0.136 | 0.712 |
>42 | 158 | 75 | 83 | |||
Gender | Male | 203 | 103 | 100 | 0.699 | 0.404 |
Female | 122 | 60 | 62 | |||
Grade | WHO II | 103 | 69 | 34 | 5.773 | 0.003 |
WHO III | 79 | 37 | 42 | |||
WHO IV | 139 | 57 | 82 | |||
IDH mutation status | Mutation | 175 | 89 | 86 | 0.139 | 0.709 |
Wildtype | 149 | 73 | 76 | |||
1p19q_Codeletion_status | Non-codel | 250 | 115 | 135 | 9.425 | 0.002 |
Codel | 67 | 44 | 23 | |||
PRS type | Primary | 229 | 123 | 106 | 0.123 | 0.884 |
Secondary | 30 | 12 | 18 | |||
Recurrent | 62 | 28 | 34 | |||
